Dissecting the role of GPR34 in cDC1 migration and function
剖析 GPR34 在 cDC1 迁移和功能中的作用
基本信息
- 批准号:10748747
- 负责人:
- 金额:$ 3.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Antigen PresentationAntigensAreaBiological AssayBiological ModelsBiologyBone MarrowCD8-Positive T-LymphocytesCaliforniaCell CommunicationCell physiologyCellsCellular AssayChemotactic FactorsChimera organismClinicalCollaborationsColon AdenocarcinomaColon CarcinomaColorectal CancerConfocal MicroscopyCross PresentationDataDendritic CellsEducational workshopEngineeringEnvironmentEnzymesEpithelial ovarian cancerFlow CytometryG-Protein-Coupled ReceptorsGenerationsGoalsGreater sac of peritoneumGrowthImmuneImmune responseImmunityImmunofluorescence ImmunologicImmunofluorescence MicroscopyImmunologyImplantIn VitroInfectionInflammationJournalsKineticsLigandsLinkLiquid substanceLymphoid TissueMC38Malignant NeoplasmsMalignant neoplasm of ovaryMeasuresMediatingMediatorMentorshipMicroanatomyMigration AssayModelingMusNatural ImmunityNeoplasm MetastasisOrganOutcomeOvalbuminPeritonealPeritonitisPhenotypePhysiciansPhysiologyPositioning AttributePostdoctoral FellowProcessProliferatingQualifyingReportingResearchRoleSan FranciscoScientistShapesSignal TransductionSiteSourceSupporting CellSystemT cell responseT-LymphocyteTechniquesTestingTherapeuticThioglycolatesTimeTrainingTumor Cell LineTumor ImmunityUniversitiesVisualizationVocational EducationWeightWorkXCR1 geneadaptive immunityantigen-specific T cellscancer cellcareercell motilitycell typeclinical trainingcolon cancer metastasisdruggable targetexperimental studyin vivoinnovationlysophosphatidylserinemedical schoolsmigrationoverexpressionpathogenreceptorrecruitresponseskillssubcutaneoussymposiumtherapeutic developmenttooltraffickingtumortumor growth
项目摘要
PROJECT SUMMARY/ABSTRACT
As critical mediators of immunity against intracellular pathogens and cancer, type 1 conventional
dendritic cells (cDC1s) cross-present exogenous, cell-associated antigens to CD8+ T cells, facilitated by the
colocalization of these two cell types in the T cell zone of secondary lymphoid tissues. This microanatomical
organization is orchestrated by CCR7 and XCR1, two G protein-coupled receptors (GPCRs) on cDC1s that
guide their migration towards gradients of chemoattractant ligand. Recent reports have established a crucial
role for tumor-associated cDC1s in cancer immunity. However, the GPCRs mediating cDC1 recruitment and
positioning at sites of inflammation and in tumors are incompletely understood.
Preliminary work has revealed that GPR34, an understudied X-linked GPCR, is highly expressed by
cDC1s, and in vitro studies have shown that this lysophosphatidylserine (lysoPS)-responsive receptor supports
cell migration. Preliminary data presented herein indicate that GPR34 promotes the accumulation of cDC1s in
the inflamed mouse peritoneal cavity (PerC) in a cell-intrinsic manner. The PerC is a clinically important site for
colon and ovarian cancer metastasis. In a preliminary experiment inspired by the connection between cDC1
accumulation and cancer outcomes, GPR34-deficiency led to increased growth of a subcutaneous (SQ) tumor
model. This proposal will test the hypothesis that GPR34 regulates cDC1 organization and function
during inflammation and cancer. Aim 1 will mechanistically define how GPR34 controls the abundance,
trafficking, and positioning of PerC cDC1s using a combination of techniques including in vivo kinetic immune
phenotyping, in vitro migration assays, and immunofluorescence microscopy. Aim 2 will investigate the role of
GPR34 and lysoPS in cancer immunity using ectopic SQ and PerC tumor models along with tools to study
antigen-specific T cell responses and to manipulate ligand levels. Completion of these Aims will elucidate key
mechanisms by which GPR34 on cDC1s influences the response to inflammation and malignancy, providing
opportunities for the development of therapeutics that modulate the lysoPS-GPR34 chemoattractant system.
These research goals will be conducted in conjunction with a comprehensive training plan to prepare
the applicant for an independent career as an academic physician-scientist. Training includes rigorous
mentorship in scientific skills from a highly qualified sponsor, Dr. Jason Cyster; technical education from
postdoctoral fellows in the applicant’s lab and collaborating labs; seminars, journal clubs, workshops, and
conferences; and clinically geared activities. Research and training will take place at the University of
California, San Francisco, which offers a highly innovative and collaborative immunology research environment
and an exceptional medical school for clinical training.
项目摘要/摘要
作为对抗细胞内病原体和癌症免疫的关键介质,1型常规
树突状细胞(CDC1s)向CD8+T细胞递送外源性的细胞相关抗原,这是由
这两种细胞类型共存于次级淋巴组织的T细胞区。这种显微解剖学
组织由CCR7和XCR1协调,这是CDC1s上的两个G蛋白偶联受体(GPCRs),
引导它们向化学诱导剂配体的梯度迁移。最近的报告已经建立了一个至关重要的
肿瘤相关CDC1s在癌症免疫中的作用。然而,GPCRs调解cDC1的招募和
炎症部位和肿瘤部位的定位尚不完全清楚。
初步工作表明,GPR34是一种未被研究的X连锁GPCR,它在
CDC1s,体外研究表明这种溶血磷脂酰丝氨酸(LysoPS)反应性受体支持
细胞迁移。初步数据表明,GPR34促进了cDC1s在体内的积累
炎症的小鼠腹膜腔(Perc)以细胞固有的方式。PERC是临床上重要的部位
结肠癌和卵巢癌转移。在一项初步实验中,灵感来自于cDc1与
GPR34缺乏导致皮下(SQ)肿瘤生长增加
模特。这一提议将检验GPR34调控cDC1组织和功能的假设
在炎症和癌症期间。目标1将机械地定义GPR34如何控制丰度,
利用包括体内运动免疫在内的多种技术组合运输和定位perc cDc1
表型鉴定、体外迁移试验和免疫荧光显微镜。目标2将调查
利用异位SQ和PERC肿瘤模型及研究工具研究GPR34和LlysoPS在肿瘤免疫中的作用
抗原特异性T细胞反应和操纵配体水平。完成这些目标将阐明关键
CDC1s上GPR34影响炎症和恶性肿瘤反应的机制
开发调节LlysoPS-GPR34化学诱导剂系统的治疗药物的机会。
这些研究目标将与全面的培训计划一起进行,以准备
作为一名学术内科医生-科学家的独立职业的申请者。培训包括严格的
来自高资质赞助商Jason Cyster博士的科学技能指导;来自
申请人实验室和合作实验室的博士后研究员;研讨会、期刊俱乐部、研讨会和
会议;与临床相关的活动。研究和培训将在华盛顿大学进行
加利福尼亚州,旧金山,提供高度创新和协作的免疫学研究环境
以及一所提供临床培训的特殊医学院。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hanson Peter Tam其他文献
Hanson Peter Tam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 3.98万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 3.98万 - 项目类别: